PMID- 25139488
OWN - NLM
STAT- MEDLINE
DCOM- 20141211
LR  - 20220419
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 15
IP  - 14
DP  - 2014 Oct
TI  - What are the pharmacotherapy options for treating prediabetes?
PG  - 2003-18
LID - 10.1517/14656566.2014.944160 [doi]
AB  - INTRODUCTION: The incidence of type 2 diabetes mellitus (T2DM) has risen to 
      epidemic proportions, and this is associated with enormous cost. T2DM is preceded 
      by 'prediabetes', and the diagnosis of impaired glucose tolerance (IGT) and/or 
      impaired fasting glucose (IFG) provides an opportunity for targeted intervention. 
      Prediabetic subjects manifest both core defects characteristic of T2DM, that is, 
      insulin resistance and beta-cell dysfunction. Interventions which improve insulin 
      sensitivity and/or preserve beta-cell function are logical strategies to delay the 
      conversion of IGT/IFG to T2DM or revert glucose tolerance to normal. AREAS 
      COVERED: The authors examine pharmacologic agents that have proven to decrease 
      the conversion of IGT to T2DM and represent potential treatment options in 
      prediabetes. EXPERT OPINION: Weight loss improves whole body insulin sensitivity, 
      preserves beta-cell function and decreases progression of prediabetes to T2DM. In 
      real life long-term weight loss is the exception and, even if successful, 40 - 
      50% of IGT individuals still progress to T2DM. Pharmacotherapy provides an 
      alternative strategy to improve insulin sensitivity and preserve beta-cell function. 
      Thiazolidinediones (TZDs) are highly effective in T2DM prevention. Long-acting 
      glucagon-like peptide-1 (GLP-1) analogs, because they augment beta-cell function and 
      promote weight loss, are effective in preventing IGT progression to T2DM. 
      Metformin is considerably less effective than TZDs or GLP-1 analogs.
FAU - Daniele, Giuseppe
AU  - Daniele G
AD  - University of Texas Health Science Center at San Antonio, Division of Diabetes , 
      7703 Floyd Curve Dr, San Antonio, TX, 78229 , USA +1 210 567 6691 ; +1 210 567 
      6554 ; albarado@uthscsa.edu.
FAU - Abdul-Ghani, Muhammad
AU  - Abdul-Ghani M
FAU - DeFronzo, Ralph A
AU  - DeFronzo RA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140819
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus, Type 2/*prevention & control
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin Resistance
MH  - Insulin-Secreting Cells/physiology
MH  - Life Style
MH  - Metformin/therapeutic use
MH  - Prediabetic State/*drug therapy/metabolism
MH  - Risk Assessment
MH  - Thiazolidinediones/therapeutic use
MH  - Weight Loss
OTO - NOTNLM
OT  - glucagon-like peptide-1 analogs
OT  - pharmacotherapy
OT  - prediabetes
OT  - weight loss
EDAT- 2014/08/21 06:00
MHDA- 2014/12/17 06:00
CRDT- 2014/08/21 06:00
PHST- 2014/08/21 06:00 [entrez]
PHST- 2014/08/21 06:00 [pubmed]
PHST- 2014/12/17 06:00 [medline]
AID - 10.1517/14656566.2014.944160 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2014 Oct;15(14):2003-18. doi: 
      10.1517/14656566.2014.944160. Epub 2014 Aug 19.